The present application is a National Phase Application of International Application No. PCT/EP2006/002771, filed Mar. 27, 2006, which claims priority to European Patent Application No. 05007157.0 filed Apr. 1, 2005, which applications are incorporated herein fully by this reference.
The present invention relates to a method for the treatment of RNA, in particular an RNA reaction method, as well as kits for performing an RNA reaction method according to the invention.
Many techniques in molecular biology lead to the analysis of ribonucleic acids (RNA). In order to be able to analyse RNA it must be purified of all inhibitory and contaminating substances. Thus, for example, contamination with genomic deoxyribonucleic acid (DNA) can have an inhibitory effect or lead to false positive results. A number of techniques of molecular RNA analysis begin with the reverse transcription of RNA into cDNA. cDNA is very similar to or even identical to genomic DNA in both structure and sequence. Therefore contamination by genomic DNA can lead to false results if cDNA is to be analysed (e.g. photometric determination of cDNA quantities or its quantification by PCR).
In order to be able to analyse RNA with certainty it is therefore necessary either to separate all other distorting nucleic acids, for example genomic DNA, from the RNA before a corresponding analysis, or to degrade them into their individual components. A separation method used for some time for DNA and RNA is the so-called density gradient centrifugation. Standard substances for density gradient centrifugation are caesium chloride (CsCl) and saccharose. In the case of CsCl a density gradient is established in the equilibrium state during centrifugation dependent upon, for example, the density of the starting solution, in which each macromolecule is aligned in the zone corresponding to its intrinsic density in the gradient. In order to visualise the nucleic acid bands established after centrifugation in the centrifugation vessel ethidium bromide is added to the CsCl solution, which is incorporated into the nucleic acid and which fluoresces in UV light. This method enables the reliable separation of individual DNA fragments which are otherwise very difficult to distinguish from one another owing to the close sedimentation rates of these fragments. In CsCl density gradient centrifugation gradients with density values between 1.0 and 1.9 g/ml are normally used. Since the buoyant density of RNA is normally greater than 1.9 g/ml, in an equilibrium centrifugation (also called isopycnic centrifugation) RNA settles to the bottom of the sample vessel in a gradient whose upper density limit lies at 1.9 g/ml, whereas all other types of molecule (including DNA) form respective bands within the gradient. Thus, corresponding separation operation leads to a good separation of RNA and DNA. However, the density gradient centrifugation method is relatively expensive owing to the chemicals used, very elaborate in apparatus and also very time consuming (in most rotors long centrifugation runs of up to 2 days are necessary until an equilibrium has been established in a conventional CsCl gradient).
Therefore a made has been made to the isolation of RNA whereby either during or after RNA preparation a DNase or several DNases is/are added to the experimental batch in order to degrade DNA contamination enzymatically. Systems (so-called “kits”) for this purpose have been marketed by the company QIAGEN, Hilden, Germany under the name “RNeasy Micro Kit” and “RNeasy Fibrous Tissue Kit” and by the company Promega, Madison/WI, USA, under the name “SV Total RNA Isolation System”. However, these RNA preparation methods do not lead to the isolation of pure RNA. The RNA isolated is present rather more as a material that is contaminated to different extents with genomic DNA, salts, inhibitors, etc. The level of purity achievable with the above-named kits may indeed be adequate for many applications, but this is not the case for a number of other areas of application (e.g. RT-PCR).
A further method for RNA purification is also used in which chromatographical methods are employed (e.g. ion exchange chromatography, oligo-dT chromatography) in order to enrich RNA further and to reduce the amount of DNA. However, it is not possible to purify ribosomal RNA with this method.
Finally, US patent application no. 20020042052 describes further a method for the removal of nucleic acid impurities from a batch for amplification reactions. Here a thermolabile DNase is used which always degrades unwanted double-stranded DNA in the amplification batch prior to the actual amplification reaction. Owing to its thermolability, the DNase used is irreversibly deactivated at the latest during the first temperature increase to above 90° C. during the PCR reaction. The PCR reaction can only then be commenced when the DNase reaction is concluded. A simultaneity of the DNA degradation reaction and an RNA reaction is thus not suggested by the method known from the cited American published specification.
Also, all these more recent methods are, however, in part time consuming, cost intensive and can possibly lead to cross-contamination during the simultaneous processing of several RNA preparations. Furthermore it is also the case with the previously known methods described above that DNA degradation does not take place concurrently with the RNA reaction or RNA analysis, but the DNA degradation is always carried out prior to the actual RNA reaction or RNA analysis.
Thus, the problem underlying the present invention is to provide a method for RNA analysis that does not have the disadvantages of the known methods described above. The new method has to be cost effective and less time consuming and keep the expenditure on apparatus within limits.
The invention solves this problem by the method according to independent Claim 1 and a kit according to the independent Claim 13. Further advantageous embodiments, aspects and details of the invention are provided by the dependent claims, the description, the examples and the figures.
The present invention thus relates to an RNA reaction method, characterised in that an RNA reaction and a degradation of double-stranded DNA present takes place in the same vessel, whereby the degradation of the double-stranded DNA is carried out by an enzyme with DNA double-strand-specific endonuclease activity. The RNA reaction and the degradation of double-stranded DNA present preferably takes place at the same time. This has the considerable advantage that it is no longer necessary to wait with the start of a RNA reaction until the unwanted double-stranded DNA present in the reaction batch has been fully degraded or at least so far degraded that it no longer interferes with the RNA reaction or the associated analysis reaction. Also, by means of the method according to the invention the risk that impurities are introduced into the reaction batch by frequent opening of the reaction vessel is reduced
Also, in the method according to the invention the RNA reaction on the one hand and the DNA degradation on the other can be carried out at the same temperature. The temperature can thereby lie, for example, in the range from 10 to 80° C., preferably 20 to 70° C., in particular 20 to 60° C.
Thus for the first time the invention combines DNA decontamination of the sample with the RNA reaction in a simultaneous process, that is, the DNA decontamination on the one hand and the RNA reaction or the RNA analysis on the other run sequentially or concurrently or in parallel in one and the same reaction vessel. Typical RNA reactions are, for example, reverse transcription, 1 step RT-PCR (reverse transcription polymerase chain reaction in one step) or tagging reactions of RNA, but are not limited to these.
The present invention thus ensures a degradation of undesirable double-stranded DNA (e.g. genomic DNA (gDNA), linear or circular DNA, e.g. plasmid DNA) at the same time as reactions that contain RNA as analyte (e.g. reverse transcription, see above). The degradation of the double-stranded DNA takes place within the reaction that contains RNA as analyte by means of an enzyme with DNA double-strand-specific endonuclease activity. This enzyme is a deoxyribonuclease (DNase) or several DNases that specifically cleaves or cleave completely or at least partially by endonucleolytic hydrolysis DNA present as an intra- or intermolecular double strand. Furthermore, these DNases are characterised in that a cleavage of DNA single strands and RNA single strands and also RNA and DNA that occur as RNA-DNA hybrids does not take place, or only to a very small extent. With this invention it is possible for the first time for a double-strand-specific DNase to be used simultaneously for the degradation of double-stranded DNA in the presence of, for example, a cDNA synthesis reaction in which an RNA is transcribed into single-stranded DNA, whereby the single-stranded cDNA just formed in the synthesis process is degraded only very slightly or not at all. The DNA double-strand-specific endonucleases that may be used according to the invention can be thermostable or thermolabile.
As previously mentioned above, the present invention relates to the combination of reduction in dsDNA contamination on the one hand and RNA reactions on the other in a simultaneous process. Important thereby are the reaction conditions that equally allow DNA degradation to take place as well as also the reaction with the RNA, whereby the dsDNA decontamination is carried out, for example, with a double-strand-specific DNase.
A “DNA contamination” in an RNA isolate is defined as any double-stranded deoxyribonucleic acid molecule which can be of different origin and occurs together with the RNA in the same reaction vessel as undesired molecule. Double-strandedness of DNA can also occur when a single-stranded DNA is present folded back through self-hybridisation and thus is present double-stranded at least for a time.
The double-stranded DNA (dsDNA) can originate from the original biological material from which the RNA has been also isolated. This can be nuclear, plastidal or mitochondrial in nature. The dsDNA can be also transferred to the original biological material from an external source by biological means, be it by infection, transformation, fusion, incorporation or similar and can thus be, for example, of viral, prokaryotic or eukaryotic origin. In addition, the DNA can also be transferred to the original biological material by unnatural means such as, for example, electroporation, transformation, transfection or other techniques. It can be genomic DNA, plasmid DNA, doubles-stranded oligonucleotides (such as, for example, primer-dimers) or other forms of double-stranded DNA. Moreover, the double-stranded DNA can also be introduced into the RNA preparation either during or after RNA isolation.
Defined as “RNA reaction” are, for example:
When in respect of the present invention discussion relates to RNA as “reaction participant” or of an “RNA reaction method”, an “RNA reaction” or an “RNA analysis”, this then means that the RNA is indeed involved in a respective reaction or analysis but must not necessarily be changed. Also, in accordance with the present invention the RNA is called a “reaction participant” in reactions from which RNA is recovered unchanged (e.g. when the RNA is used as catalyst or matrix), or when discussion refers to an “RNA reaction method”, an RNA reaction” or an “RNA analysis”.
If in connection with the present invention use is made of “at the same time” or simultaneity”, “in parallel”, “simultaneous” or similar it is to be understood that a dsDNA degradation and the RNA reaction takes place in the same reaction vessel. Degradation of the dsDNA contamination and the RNA reaction are thus carried out at the same time and in the one and the same reaction batch. Simultaneity is meant to express that the RNA reaction and a degradation of the dsDNA contamination takes place at the same time in the same reaction vessel and under the same reaction conditions.
It is also advantageous in the method according to the invention, in particular opposite the method known from US 20020042052, that the method according to the invention can take place at a uniform temperature, that is that the RNA reaction and a dsDNA degradation can take place at the same temperature. In addition, it is also beneficial opposite the method known from US 20020042052 that in the method according to the invention it is not necessary to open the reaction vessel again after the dsDNA degradation with DNase and to add a new enzyme (that would possible be irreversibly damaged by warming to over 90° C.) as in that way unnecessary contamination can be avoided.
According to the present invention the RNA reaction is limited by the reaction conditions which not only determine the RNA reaction, but simultaneously should also allow the degradation of the dsDNA contamination. This does not mean that optimal conditions are set respectively for the reaction of the RNA and for degradation of the dsDNA, but the conditions for the RNA reaction and a degradation of the DNA can throughout be adapted to one another. The present invention makes it possible for the first time for an RNA reaction and degradation of dsDNA to take place at the same time in the one and the same reaction vessel.
A “deoxyribonuclease”, or abbreviated “DNase”, is defined here as an enzyme that specifically completely or at least partially cleaves (degrades) by endonucleolytic hydrolysis DNA present as a intra- or intermolecular double strand, that is an enzyme with DNA double-strand-specific DNA endonuclease activity. This DNase is thus characterised in that a degradation or cleavage of RNA single strands and of DNA single strands and also of a RNA or DNA that is present as RNA-DNA hybrid does not take place or only to a negligibly small extent. The DNases within the meaning of the present invention are either sequence-specific or cleave the dsDNA non-specifically. Both variants can be used within the context of the present invention. It is likewise possible to use thermolabile and/or thermostable DNases. Thus it is clear to the appropriate person skilled in the art in the light of the respective RNA reaction or also of the respective follow-up reaction which enzyme is suitable.
By a “degradation” of the dsDNA it is to be understood that the degradation process progresses so far in every case that the DNA shows only a slight or no a disruptive effect on the RNA reaction(s) or the subsequent applications. A degradation can, but need not necessarily, mean a complete disintegration of double-stranded DNA into its individual components (nucleotides). Within the meaning of the invention the degradation of the dsDNA occurs at least partially at the same time as the RNA reaction.
The diagrams show:
The following enzymes can be used for the degradation of double-stranded DNA, in particular in reverse transcriptase reactions:
The endonucleases are generally used in such a manner that the reaction batch contains about 0.01 to about 100 U of enzyme activity, preferably about 0.05 to about 20 U, more preferably about 0.1 to about 10 U. According to international agreement, enzyme activity expressed as 1 U (unit, enzyme unit) corresponds to a) for sequence-non-specific DNA double-strand-specific endonucleases the amount of enzyme that is necessary to convert 1 μmol substrate per minute at 25° C. under optimal conditions, and b) for sequence-specific DNA double-strand-specific restriction endonucleases the amount of enzyme that is necessary to convert 1 μg Lambda-DNA per hour at 37° C. under optimal conditions.
In the case of an RT-PCR the degradation of the dsDNA is carried out in the presence of a reverse transcriptase. Suitable reverse transcriptases are, for example, reverse transcriptases from retroviruses such as, for example, HIV, AMV, MMLV, Omniscript® (QIAGEN GmbH), Sensiscript® (QIAGEN GmbH) etc., or also from retrotransposons. The reverse transcriptases can correspond to the original organism in their amino acid sequence, or they can also have deviations therefrom, for example, changes that lead to loss of RNase H activity, change the processivity or influence the thermostability of the enzyme. DNA polymerases which originally have little or no reverse transcriptase activity can also be used and can be used as reverse transcriptase through the use of suitable reaction conditions or through mutations (e.g. rTth polymerase).
The aqueous buffer solution in which the degradation dsDNA takes place in the presence of reverse transcriptase comprises at least:
The reaction batch can also contain other components such as, for example, other enzymes, divalent cations or salts. A heat-stable DNA polymerase can thus also be present.
The reaction temperature can lie, for example, between 10 and 70° C., preferably between 15° C. and 60° C., most particularly preferred between 20° C. and 50° C.
The present invention relates further to a kit for performing a method according to any of claims 1 to 12, whereby the kit comprises at least one reverse transcriptase, a DNA double-strand-specific endonuclease and a reaction buffer for performing a method according to any of the claims 1 to 12 and a dsDNA degradation in one vessel. Preferably the kits are such for performing a cDNA synthesis or for undertaking a 1-step RT-PCR. If the kit serves the performing of a 1-step PCR it can additionally contain a heat-stable DNA polymerase.
The invention is described more closely in the following by means of the examples.
In each case 1 μg gDNA and 1 μg total-RNA from HeLa cells were mixed for use in a reverse transcriptase reaction. The reverse transcriptase reaction was carried out in an aqueous medium that contained an oligo-dT primer, dNTPs, an RNase inhibitor, a buffer (Buffer RT from the Omniscript RT Kit of QIAGEN GmbH, Hilden, Germany) for the reverse transcription and a reverse transcriptase (Omniscript®, trademark of QIAGEN GmbH, Hilden, Germany). In addition different double-strand-specific DNases were added:
No DNase was added to an additional reaction batch. This batch served as control. The reaction mixture was incubated for one hour at 37° C. and then (A) analysed by PCR for cDNA degradation and (B) tested for RNA integrity and DNA degradation on an agarose gel (1.2%).
The result is shown in
Each time 1 ng total RNA from HeLa cells was mixed with 1 μg of a 0.2-9.5 kB RNA-ladder (Invitrogen) for use in a reverse transcriptase reaction. The reverse transcriptase reaction was carried out in an aqueous medium that contained an oligo-dT primer, dNTPs, RNase inhibitor, a buffer (Buffer RT from the Omniscript RT Kit of QIAGEN GmbH, Hilden, Germany) for the reverse transcription and a reverse transcriptase (Omniscript®, trade mark of QIAGEN GmbH, Hilden, Germany). In addition the DNA double-strand-specific-endonuclease DNase I (RNase-free DNase I) was added. Exonuclease VII (“Exo VII”) was added to further batches.
The DNase I (from bovine pancreas; obtainable from Roche, Mannheim, Germany) and the exonuclease VII were used in different amounts. No nuclease was added to a further reaction batch. This batch served as positive control. The batch with exonuclease VII served as negative control. Exonuclease VII is not double-strand-specific and able to degrade single-stranded DNA. The respective reaction mixtures were incubated for one hour at 37° C. and then analysed by PCR for cDNA degradation. The whole β-actin transcript was amplified in the PCR.
The result is shown in
Each of 1 μg genomic DNA and 1 μg total-RNA from HeLa cells were mixed for use in a reverse transcriptase reaction. The reverse transcriptase reaction was carried out in an aqueous medium that contained an oligo-dT primer, dNTPs, an RNase inhibitor and a buffer (Buffer RT from the Omniscript RT Kit of QIAGEN GmbH, Hilden, Germany) for the reverse transcription. In addition different amounts of double-strand-specific nucleases were added:
Reverse transcriptase was added to one set of the batches in order to be able to investigate the influence of nucleases on the synthesis of single-stranded cDNA. No reverse transcriptase was added to a second set of batches in order to be able to follow the degradation of genomic DNA. The reaction mixtures were incubated for one hour at 37° C. and then analysed by PCR. In the batches in which cDNA synthesis was followed the complete cDNA of the β-actin transcript was amplified. In the batches in which the degradation of genomic DNA was followed a region from the 5′-end of the β-actin gene was amplified. Since the primer set spans an intron the genomic amplificate shows a size of >600 bp, whereas the amplificate of the cDNA has a size of ca. 200 bp.
The result is shown in
Each time 150 ng total RNA from HeLa cells were mixed with 150 ng gDNA in order to carry out a DNase reaction under reverse transcriptase reaction conditions. The reaction was carried out in an aqueous medium that contained oligo-dT primer, dNTPs, an RNase inhibitor and a buffer (Buffer RT from the Omniscript RT Kit of QIAGEN GmbH, Hilden, Germany) for the reverse transcription. In addition 0; 0.1; 0.5; or 2.5 units double-strand-specific nuclease (RNase-free DNase I) were added to the batches. Also 0 mM, 0.5 mM, 1 mM, 1.5 mM, 2 mM or 2.5 mM magnesium chloride were added to the batches. No reverse transcriptase was added in order to investigate the DNase I activity under reverse transcriptase reaction conditions. The reaction mixtures were incubated for one hour at 37° C. The DNA degradation was then analysed by quantitative real-time PCR. For this 1 μl of the reaction mixture each time was used for the real-time PCR. A primer pair that amplified a 200 bp fragment from the 5′-end of the β-actin was used. The resulting amplificate was detected with SYBR green.
The result is shown in
Each time 150 ng total RNA from HeLa cells were mixed with 0 ng or 150 ng gDNA for use in a reverse transcriptase reaction. The reaction was carried out in an aqueous medium that contained an oligo-dT primer, dNTPs, RNase inhibitor and a buffer (Buffer RT from the Omniscript RT Kit of QIAGEN GmbH, Hilden, Germany) for the revere transcription. In addition, 2.5 units of double-strand-specific endonuclease (RNase-free DNase I) are added to a part of the batches. One set of the batches received a reverse transcriptase in order to be able to investigate the influence of the nucleases on the synthesis of single-stranded cDNA. No reverse transcriptase was added to a second batch in order to be able follow the degradation of the genomic DNA. The reaction mixtures were incubated for one hour at 37° C. The cDNA synthesis and the DNA degradation were then analysed by quantitative real time PCR. In each case 1 μl and 0.1 μl of the reverse transcriptase reaction were used for the real time PCR. A primer pair that amplified a 210 bp fragment from the 3′-end of the β-actin was used. The resulting amplificate was detected with SYBR green.
The result of this investigation was that the reverse transcription was not impaired by the presence of RNase-free DNase I. By use of RNase-free DNase I the genomic DNA was degraded more than 1000 times. At the same time the cDNA generated was not, or only insignificantly, digested. The result is collated in Table 2.
The DNase step can also be carried out in a very brief reaction before the actual RNA-modifying reaction, whereby, however, as in the above batches the DNase remains in the reaction mixture and is not removed from the system by heat inactivation or a purification step.
Each time 10 μg to 1 μg total RNA from HeLa cells were mixed with identical amounts of gDNA for use in a reverse transcriptase reaction. The reaction was carried out in an aqueous medium that contained an oligo-dT primer, random octamers, dNTPs, RNase inhibitor and a buffer (gDNA Wipeout Buffer and Quantiscript RT Buffer from the QuantiTecto Reverse Transcription Kit of QIAGEN GmbH, Hilden, Germany) for the reverse transcription. Also 2.5 units double-strand-specific endonuclease (RNase-free DNase I) were added to a part of the batches. Reverse transcriptase was added to one set of the batches in order to be able to investigate the influence of the nucleases on the synthesis of single-stranded cDNA. No reverse transcriptase was added to a second set of batches in order to be able to follow the degradation of genomic DNA. Before the actual cDNA synthesis the DNase step was carried out for 2 minutes at 37° C. Only then were the reaction mixtures incubated for 15 minutes in the presence of the reverse transcriptase at 37° C. Next, the cDNA synthesis and the DNA degradation analysed by quantitative real time PCR. In each case 1 μl of the reverse transcriptase reaction was used for the real time PCR. A QuantiTect Gene Expression Assay (QIAGEN GmbH, Hilden, Germany) was used for the Gen RPSLA, together with the QuantiTect Probe PCR Kit (also from QIAGEN), which contains all necessary reaction components such as HotStar Taq DNA Polymerase (QIAGEN), reaction buffer and dNTPs. The HotStar Taq DNA Polymerase was reactivated for 15 minutes at 95° C., after which the PCR was carried out for 50 cycles with the following temperature profile: 15 sec 56° C., 30 sec 76° C., 30 sec 94° C. The reverse transcriptase reaction was deactivated for 5 min at 95° C. before use in the PCR reaction. The extent of the genomic DNA depletion is reported in the following table 3 in CT values:
The result shows that by use of RNase-free DNase I, whose incubation is carried out prior to the actual reverse transcriptase step, the genomic DNA is generally depleted more than 1000 times.
A further batch was used to demonstrate that the DNase step can also be integrated into the process of a so-called 1-step RT-PCR. In a 1-step RT-PCR reaction the whole reaction batch including all reagents necessary for the reverse transcriptase step and the subsequent PCR step are combined. The reaction is started with the reverse transcription and continues directly into the PCR step without opening the reaction vessel. The following example shows that a DNase step can also be introduced into such a continuous method scheme that does not allow further operator interaction.
In each case 20 ng total RNA from HeLa cells and 20 ng high molecular gDNA were used in each 1-step RT-PCR. 150 μM CaCl2 were added to the reaction. Each reaction was carried out with the QuantiTect RT-PCR Kit (QIAGEN GmbH, Hilden, Germany), which contains all necessary reaction components such as reverse transcriptase, HotStar Taq DNA polymerase, reaction buffer and dNTPs. The reactions were initiated with and without DNase I. The reverse transcriptase was not used in reactions that were solely to detect genomic DNA in order not to obtain an additional signal from the cDNA. Reaction batches in which DNase I was used received 0.25 units DNase I. A transcript region for which identical sequences occur in genomic DNA was detected as target gene. The PCR products that were generated from genomic DNA and cDNA had the same size and consequently should be amplified and detected with the same efficiency.
The result is shown in
Number | Date | Country | Kind |
---|---|---|---|
05007157 | Apr 2005 | EP | regional |
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/EP2006/002771 | 3/27/2006 | WO | 00 | 10/6/2009 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2006/103039 | 10/5/2006 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
2264423 | Wingenroth | Dec 1941 | A |
3395018 | Read | Jul 1968 | A |
3654090 | Wilhelmus et al. | Apr 1972 | A |
3687808 | Merigan, Jr. et al. | Aug 1972 | A |
3921105 | Brgelz | Nov 1975 | A |
3983421 | Yogore | Sep 1976 | A |
3995018 | Sjoquist | Nov 1976 | A |
4299916 | Litman et al. | Nov 1981 | A |
4469863 | Ts'o et al. | Sep 1984 | A |
4476301 | Imbach et al. | Oct 1984 | A |
4748111 | Dattagupta et al. | May 1988 | A |
4816567 | Cabilly et al. | Mar 1989 | A |
4837003 | Nicolotti | Jun 1989 | A |
4845205 | Huynh Dinh et al. | Jul 1989 | A |
4883750 | Whiteley et al. | Nov 1989 | A |
4937183 | Ultee et al. | Jun 1990 | A |
4940670 | Rhodes | Jul 1990 | A |
4965188 | Mullis et al. | Oct 1990 | A |
4981957 | Lebleu et al. | Jan 1991 | A |
4994373 | Stavrianopoulos et al. | Feb 1991 | A |
4994557 | Kassis et al. | Feb 1991 | A |
5001050 | Blanco et al. | Mar 1991 | A |
5023243 | Tullis | Jun 1991 | A |
5034506 | Summerton et al. | Jul 1991 | A |
5043272 | Hartley | Aug 1991 | A |
5106727 | Hartley et al. | Apr 1992 | A |
5118800 | Smith et al. | Jun 1992 | A |
5130238 | Malek et al. | Jul 1992 | A |
5130302 | Spielvogel et al. | Jul 1992 | A |
5134066 | Rogers et al. | Jul 1992 | A |
5137806 | LeMaistre et al. | Aug 1992 | A |
5166315 | Summerton et al. | Nov 1992 | A |
5175273 | Bischofberger et al. | Dec 1992 | A |
5177196 | Meyer, Jr. et al. | Jan 1993 | A |
5185444 | Summerton et al. | Feb 1993 | A |
5187060 | Cerutti et al. | Feb 1993 | A |
5188897 | Suhadolnik et al. | Feb 1993 | A |
5198543 | Blanco et al. | Mar 1993 | A |
5214134 | Weis et al. | May 1993 | A |
5216141 | Benner | Jun 1993 | A |
5235033 | Summerton et al. | Aug 1993 | A |
5242794 | Whiteley et al. | Sep 1993 | A |
5262311 | Pardee et al. | Nov 1993 | A |
5264423 | Cohen et al. | Nov 1993 | A |
5264562 | Matteucci | Nov 1993 | A |
5264564 | Matteucci | Nov 1993 | A |
5264567 | Numata et al. | Nov 1993 | A |
5268486 | Waggoner et al. | Dec 1993 | A |
5273638 | Konrad et al. | Dec 1993 | A |
5276019 | Cohen et al. | Jan 1994 | A |
5278302 | Caruthers et al. | Jan 1994 | A |
5286717 | Cohen et al. | Feb 1994 | A |
5319080 | Leumann | Jun 1994 | A |
5321131 | Agrawal et al. | Jun 1994 | A |
5328824 | Ward et al. | Jul 1994 | A |
5334711 | Sproat et al. | Aug 1994 | A |
5354668 | Auerbach | Oct 1994 | A |
5359044 | Cook et al. | Oct 1994 | A |
5367066 | Urdea et al. | Nov 1994 | A |
5367069 | Beck et al. | Nov 1994 | A |
5393878 | Leumann | Feb 1995 | A |
5399676 | Froehler | Mar 1995 | A |
5405938 | Summerton et al. | Apr 1995 | A |
5405939 | Suhadolnik et al. | Apr 1995 | A |
5409818 | Davey et al. | Apr 1995 | A |
5412087 | McGall et al. | May 1995 | A |
5427930 | Birkenmeyer et al. | Jun 1995 | A |
5429807 | Matson et al. | Jul 1995 | A |
5432272 | Benner | Jul 1995 | A |
5434257 | Matteucci et al. | Jul 1995 | A |
5443986 | Haughland et al. | Aug 1995 | A |
5445934 | Fodor et al. | Aug 1995 | A |
5446137 | Maag et al. | Aug 1995 | A |
5451067 | Pieper | Sep 1995 | A |
5451203 | Lamb | Sep 1995 | A |
5453496 | Caruthers et al. | Sep 1995 | A |
5455166 | Walker | Oct 1995 | A |
5455233 | Spielvogel et al. | Oct 1995 | A |
5457187 | Gmeiner et al. | Oct 1995 | A |
5459255 | Cook et al. | Oct 1995 | A |
5466677 | Baxter et al. | Nov 1995 | A |
5466786 | Buhr et al. | Nov 1995 | A |
5470967 | Huie et al. | Nov 1995 | A |
5476427 | Fujima | Dec 1995 | A |
5476786 | Huston | Dec 1995 | A |
5476925 | Letsinger et al. | Dec 1995 | A |
5484908 | Froehler et al. | Jan 1996 | A |
5489677 | Sanghvi et al. | Feb 1996 | A |
5500341 | Spears | Mar 1996 | A |
5502177 | Matteucci et al. | Mar 1996 | A |
5510270 | Fodor et al. | Apr 1996 | A |
5514785 | Van Ness et al. | May 1996 | A |
5516134 | Crawford et al. | May 1996 | A |
5516663 | Backman et al. | May 1996 | A |
5516664 | Hyman | May 1996 | A |
5519126 | Hecht | May 1996 | A |
5519134 | Acevedo et al. | May 1996 | A |
5521065 | Whiteley et al. | May 1996 | A |
5523204 | Singer et al. | Jun 1996 | A |
5525711 | Hawkins et al. | Jun 1996 | A |
5536821 | Agrawal et al. | Jul 1996 | A |
5538871 | Nuovo et al. | Jul 1996 | A |
5539082 | Nielsen et al. | Jul 1996 | A |
5541306 | Agrawal et al. | Jul 1996 | A |
5541307 | Cook et al. | Jul 1996 | A |
5547843 | Studier et al. | Aug 1996 | A |
5550111 | Suhadolnik et al. | Aug 1996 | A |
5552540 | Haralambidis | Sep 1996 | A |
5556748 | Douglas | Sep 1996 | A |
5556771 | Shen et al. | Sep 1996 | A |
5556772 | Sorge et al. | Sep 1996 | A |
5561045 | Dorval et al. | Oct 1996 | A |
5561225 | Maddry et al. | Oct 1996 | A |
5563037 | Sutherland et al. | Oct 1996 | A |
5563253 | Agrawal et al. | Oct 1996 | A |
5563912 | Yasunaga et al. | Oct 1996 | A |
5565339 | Bloch et al. | Oct 1996 | A |
5567811 | Misiura et al. | Oct 1996 | A |
5571799 | Tkachuk et al. | Nov 1996 | A |
5576427 | Cook et al. | Nov 1996 | A |
5587361 | Cook et al. | Dec 1996 | A |
5587469 | Cook et al. | Dec 1996 | A |
5591609 | Auerbach | Jan 1997 | A |
5591722 | Montgomery et al. | Jan 1997 | A |
5593836 | Niemiec et al. | Jan 1997 | A |
5594121 | Froehler et al. | Jan 1997 | A |
5596086 | Matteucci et al. | Jan 1997 | A |
5596091 | Switzer | Jan 1997 | A |
5597909 | Urdea et al. | Jan 1997 | A |
5599695 | Pease et al. | Feb 1997 | A |
5599921 | Sorge et al. | Feb 1997 | A |
5602240 | De Mesmaeker et al. | Feb 1997 | A |
5608046 | Cook et al. | Mar 1997 | A |
5610289 | Cook et al. | Mar 1997 | A |
5610300 | Altmann et al. | Mar 1997 | A |
5614389 | Auerbach | Mar 1997 | A |
5614390 | McCaslin et al. | Mar 1997 | A |
5614617 | Cook et al. | Mar 1997 | A |
5618704 | Sanghvi et al. | Apr 1997 | A |
5623070 | Cook et al. | Apr 1997 | A |
5625050 | Beaton et al. | Apr 1997 | A |
5627053 | Usman et al. | May 1997 | A |
5629158 | Uhlen | May 1997 | A |
5629179 | Mierendorf et al. | May 1997 | A |
5633360 | Bischofberger et al. | May 1997 | A |
5635602 | Cantor et al. | Jun 1997 | A |
5639599 | Ryder et al. | Jun 1997 | A |
5639873 | Barascut et al. | Jun 1997 | A |
5646265 | McGee | Jul 1997 | A |
5648213 | Reddy et al. | Jul 1997 | A |
5648245 | Fire et al. | Jul 1997 | A |
5654413 | Brenner | Aug 1997 | A |
5658873 | Bertsch-Frank et al. | Aug 1997 | A |
5663312 | Chaturvedula | Sep 1997 | A |
5665539 | Sano et al. | Sep 1997 | A |
5670633 | Cook et al. | Sep 1997 | A |
5677437 | Teng et al. | Oct 1997 | A |
5677439 | Weis et al. | Oct 1997 | A |
5679509 | Wheeler et al. | Oct 1997 | A |
5681941 | Cook et al. | Oct 1997 | A |
5683985 | Chu et al. | Nov 1997 | A |
5691136 | Lupski et al. | Nov 1997 | A |
5695933 | Schalling et al. | Dec 1997 | A |
5700920 | Altmann et al. | Dec 1997 | A |
5710028 | Eyal et al. | Jan 1998 | A |
5712100 | Nakahama et al. | Jan 1998 | A |
5714320 | Kool | Feb 1998 | A |
5714331 | Buchardt et al. | Feb 1998 | A |
5719262 | Buchardt et al. | Feb 1998 | A |
5728526 | George, Jr. et al. | Mar 1998 | A |
5733733 | Auerbach | Mar 1998 | A |
5736365 | Walker et al. | Apr 1998 | A |
5744305 | Fodor et al. | Apr 1998 | A |
5766891 | Shuman | Jun 1998 | A |
5770408 | Sato | Jun 1998 | A |
5795714 | Cantor et al. | Aug 1998 | A |
5800992 | Fodor et al. | Sep 1998 | A |
5800994 | Martinelli et al. | Sep 1998 | A |
5807674 | Tyagi | Sep 1998 | A |
5817529 | Wu | Oct 1998 | A |
5821084 | Olmsted et al. | Oct 1998 | A |
5824517 | Cleuziat et al. | Oct 1998 | A |
5830711 | Barany et al. | Nov 1998 | A |
5849544 | Harris et al. | Dec 1998 | A |
5854033 | Lizardi | Dec 1998 | A |
5856096 | Windle et al. | Jan 1999 | A |
5866329 | Demetriou et al. | Feb 1999 | A |
5866336 | Nazarenko et al. | Feb 1999 | A |
5871697 | Rothberg et al. | Feb 1999 | A |
5871914 | Nathan | Feb 1999 | A |
5871921 | Landegren et al. | Feb 1999 | A |
5871928 | Fodor et al. | Feb 1999 | A |
5874260 | Cleuziat et al. | Feb 1999 | A |
5876924 | Zhang et al. | Mar 1999 | A |
5876932 | Fischer | Mar 1999 | A |
5876992 | De Rosier et al. | Mar 1999 | A |
5880473 | Ginestet | Mar 1999 | A |
5882912 | Sandstrom et al. | Mar 1999 | A |
5882935 | Hirai et al. | Mar 1999 | A |
5886329 | Kim | Mar 1999 | A |
5888731 | Yager et al. | Mar 1999 | A |
5891636 | Van Gelder et al. | Apr 1999 | A |
5909132 | Trofimenkoff et al. | Jun 1999 | A |
5912124 | Kumar | Jun 1999 | A |
5912148 | Eggerding | Jun 1999 | A |
5914229 | Loewy | Jun 1999 | A |
5925517 | Tyagi et al. | Jul 1999 | A |
5942391 | Zhang et al. | Aug 1999 | A |
5942609 | Hunkapiller et al. | Aug 1999 | A |
5945312 | Goodman et al. | Aug 1999 | A |
5955933 | Nishihara et al. | Sep 1999 | A |
5959095 | Martinelli et al. | Sep 1999 | A |
5962223 | Whiteley et al. | Oct 1999 | A |
5968743 | Matsunaga et al. | Oct 1999 | A |
5976806 | Mahajan et al. | Nov 1999 | A |
5985639 | Christianson et al. | Nov 1999 | A |
5998175 | Akhavan-Tafti | Dec 1999 | A |
6007994 | Ward et al. | Dec 1999 | A |
6008373 | Waggoner et al. | Dec 1999 | A |
6013431 | Soderlund et al. | Jan 2000 | A |
6013444 | Dau et al. | Jan 2000 | A |
6017703 | Kinders et al. | Jan 2000 | A |
6020138 | Akhavan-Tafti | Feb 2000 | A |
6025139 | Yager et al. | Feb 2000 | A |
6027889 | Barany et al. | Feb 2000 | A |
6027923 | Wallace | Feb 2000 | A |
6033881 | Himmler et al. | Mar 2000 | A |
6037130 | Tyagi et al. | Mar 2000 | A |
6054274 | Sampson et al. | Apr 2000 | A |
6057105 | Hoon et al. | May 2000 | A |
6064274 | Nayebi et al. | May 2000 | A |
6077668 | Kool | Jun 2000 | A |
6077674 | Schleifer et al. | Jun 2000 | A |
6087133 | Dattagupta et al. | Jul 2000 | A |
6087476 | Kenten et al. | Jul 2000 | A |
6096880 | Kool | Aug 2000 | A |
6117635 | Nazarenko et al. | Sep 2000 | A |
6124120 | Lizardi | Sep 2000 | A |
6132728 | Beachy et al. | Oct 2000 | A |
6140055 | Todd et al. | Oct 2000 | A |
6143495 | Lizardi et al. | Nov 2000 | A |
6169816 | Ravkin | Jan 2001 | B1 |
6183960 | Lizardi | Feb 2001 | B1 |
6197533 | Dawkes et al. | Mar 2001 | B1 |
6203984 | Hu et al. | Mar 2001 | B1 |
6210884 | Lizardi | Apr 2001 | B1 |
6214587 | Dattagupta et al. | Apr 2001 | B1 |
6221603 | Mahtani | Apr 2001 | B1 |
6225636 | Ginestet | May 2001 | B1 |
6235502 | Weissman et al. | May 2001 | B1 |
6242188 | Dattagupta et al. | Jun 2001 | B1 |
6248535 | Danenberg et al. | Jun 2001 | B1 |
6255082 | Lizardi | Jul 2001 | B1 |
6255636 | Cochran, II et al. | Jul 2001 | B1 |
6259807 | Ravkin | Jul 2001 | B1 |
6274320 | Rothberg et al. | Aug 2001 | B1 |
6277607 | Tyagi et al. | Aug 2001 | B1 |
6280949 | Lizardi | Aug 2001 | B1 |
6287765 | Cubicciotti | Sep 2001 | B1 |
6287768 | Chenchik et al. | Sep 2001 | B1 |
6287776 | Hefti | Sep 2001 | B1 |
6287824 | Lizardi | Sep 2001 | B1 |
6288220 | Kambara et al. | Sep 2001 | B1 |
6291183 | Pirrung et al. | Sep 2001 | B1 |
6291187 | Kingsmore et al. | Sep 2001 | B1 |
6291193 | Khodadoust | Sep 2001 | B1 |
6291669 | Kwiatkowski et al. | Sep 2001 | B1 |
6294664 | Ravikumar et al. | Sep 2001 | B1 |
6297006 | Drmanac et al. | Oct 2001 | B1 |
6300073 | Zhao et al. | Oct 2001 | B1 |
6312902 | Shultz et al. | Nov 2001 | B1 |
6316229 | Lizardi et al. | Nov 2001 | B1 |
6323009 | Lasken et al. | Nov 2001 | B1 |
6329150 | Lizardi et al. | Dec 2001 | B1 |
6344329 | Lizardi | Feb 2002 | B1 |
6355431 | Chee et al. | Mar 2002 | B1 |
6361940 | Van Ness et al. | Mar 2002 | B1 |
6365729 | Tyagi et al. | Apr 2002 | B1 |
6368801 | Faruqi | Apr 2002 | B1 |
6403319 | Lizardi et al. | Jun 2002 | B1 |
6417340 | Mirkin et al. | Jul 2002 | B1 |
6440707 | Kwok et al. | Aug 2002 | B1 |
6458544 | Miller | Oct 2002 | B1 |
6458556 | Hayashizaki | Oct 2002 | B1 |
6472185 | McCasky Feazel et al. | Oct 2002 | B2 |
6475736 | Stanton, Jr. | Nov 2002 | B1 |
6479235 | Schumm et al. | Nov 2002 | B1 |
6479242 | Guo et al. | Nov 2002 | B1 |
6479244 | Belouchi et al. | Nov 2002 | B1 |
6498023 | Abarzua | Dec 2002 | B1 |
6506563 | Ward et al. | Jan 2003 | B1 |
6531283 | Kingsmore et al. | Mar 2003 | B1 |
6573051 | Alsmadi et al. | Jun 2003 | B2 |
6617137 | Dean et al. | Sep 2003 | B2 |
6632609 | Lizardi | Oct 2003 | B2 |
6635425 | Bandaru et al. | Oct 2003 | B2 |
6642034 | Lizardi | Nov 2003 | B2 |
6670126 | Kingsmore et al. | Dec 2003 | B2 |
6686157 | Ward et al. | Feb 2004 | B2 |
6703228 | Landers et al. | Mar 2004 | B1 |
6703885 | Fan et al. | Mar 2004 | B1 |
6706519 | Kellogg et al. | Mar 2004 | B1 |
6713257 | Shoemaker et al. | Mar 2004 | B2 |
6777183 | Abarzua | Aug 2004 | B2 |
6797474 | Lizardi | Sep 2004 | B2 |
6811986 | Bandaru et al. | Nov 2004 | B2 |
6830884 | Hafner et al. | Dec 2004 | B1 |
6861222 | Ward et al. | Mar 2005 | B2 |
6861231 | Shao | Mar 2005 | B2 |
6884586 | Van Ness et al. | Apr 2005 | B2 |
6921642 | Kingsmore et al. | Jul 2005 | B2 |
6942972 | Farooqui et al. | Sep 2005 | B2 |
6977148 | Dean et al. | Dec 2005 | B2 |
6977153 | Kumar et al. | Dec 2005 | B2 |
RE39007 | Dattagupta et al. | Mar 2006 | E |
7041480 | Abarzua | May 2006 | B2 |
7074600 | Dean et al. | Jul 2006 | B2 |
7297485 | Bornarth et al. | Nov 2007 | B2 |
7358047 | Hafner et al. | Apr 2008 | B2 |
7553619 | Kumar et al. | Jun 2009 | B2 |
7618776 | Lizardi | Nov 2009 | B2 |
20010041340 | Kingsmore et al. | Nov 2001 | A1 |
20020009716 | Abarzua | Jan 2002 | A1 |
20020026046 | Pasloske et al. | Feb 2002 | A1 |
20020042052 | Nilsen et al. | Apr 2002 | A1 |
20020119465 | Zhao et al. | Aug 2002 | A1 |
20020120409 | Cao et al. | Aug 2002 | A1 |
20020172972 | Tabor et al. | Nov 2002 | A1 |
20020192649 | Lizardi | Dec 2002 | A1 |
20020192658 | Ward et al. | Dec 2002 | A1 |
20020197694 | Shao | Dec 2002 | A1 |
20030008313 | Wiltshire | Jan 2003 | A1 |
20030022167 | Alsmadi et al. | Jan 2003 | A1 |
20030032014 | Wei et al. | Feb 2003 | A1 |
20030032024 | Lizardi | Feb 2003 | A1 |
20030059786 | Ward et al. | Mar 2003 | A1 |
20030092901 | Farooqui et al. | May 2003 | A1 |
20030099954 | Miltenyi et al. | May 2003 | A1 |
20030108902 | Abarzua | Jun 2003 | A1 |
20030121338 | Yates | Jul 2003 | A1 |
20030129658 | Yamaji et al. | Jul 2003 | A1 |
20030143613 | Kingsmore et al. | Jul 2003 | A1 |
20030152932 | Kumar et al. | Aug 2003 | A1 |
20030165948 | Alsmadi et al. | Sep 2003 | A1 |
20030175788 | Alsmadi et al. | Sep 2003 | A1 |
20030186288 | Spivack et al. | Oct 2003 | A1 |
20030207267 | Lasken et al. | Nov 2003 | A1 |
20030207323 | Bandaru et al. | Nov 2003 | A1 |
20030219751 | Lao et al. | Nov 2003 | A1 |
20030235849 | Lizardi et al. | Dec 2003 | A1 |
20040018489 | Ma et al. | Jan 2004 | A1 |
20040063144 | Lizardi | Apr 2004 | A1 |
20040091857 | Nallur et al. | May 2004 | A1 |
20040121338 | Alsmadi et al. | Jun 2004 | A1 |
20040126770 | Kumar et al. | Jul 2004 | A1 |
20040191784 | Abarzua et al. | Sep 2004 | A1 |
20040248103 | Feaver et al. | Dec 2004 | A1 |
20040248105 | Kumar | Dec 2004 | A1 |
20040265897 | Lizardi | Dec 2004 | A1 |
20050003369 | Christians et al. | Jan 2005 | A1 |
20050003410 | Frazer et al. | Jan 2005 | A1 |
20050069938 | Wang | Mar 2005 | A1 |
20050069939 | Wang | Mar 2005 | A1 |
20050074804 | Wang | Apr 2005 | A1 |
20050079523 | Hafner et al. | Apr 2005 | A1 |
20050112639 | Wang | May 2005 | A1 |
20060083683 | Hsei et al. | Apr 2006 | A1 |
20060126764 | Eklund et al. | Jun 2006 | A1 |
20060166227 | Kingsmore et al. | Jul 2006 | A1 |
20060188892 | Latham et al. | Aug 2006 | A1 |
20080096258 | Korfhage et al. | Apr 2008 | A1 |
20110112173 | Brown et al. | May 2011 | A1 |
Number | Date | Country |
---|---|---|
8417391 | Feb 1992 | AU |
649066 | May 1994 | AU |
5850996 | Nov 1996 | AU |
714486 | Jan 2000 | AU |
749560 | Jun 2002 | AU |
0 070 685 | Jul 1982 | EP |
0 128 332 | Dec 1984 | EP |
0 310 030 | Apr 1989 | EP |
0 320 308 | Jun 1989 | EP |
0 356 021 | Feb 1990 | EP |
0 379 369 | Jul 1990 | EP |
0 395 398 | Oct 1990 | EP |
0 439 182 | Jul 1991 | EP |
0 466 520 | Jan 1992 | EP |
0 505 012 | Sep 1992 | EP |
0 531 080 | Mar 1993 | EP |
0 278 340 | Aug 1993 | EP |
0278340 | Aug 1993 | EP |
0 640 691 | Mar 1995 | EP |
0 667 393 | Aug 1995 | EP |
0 678 582 | Oct 1995 | EP |
0 745 690 | Dec 1996 | EP |
0 756 009 | Jan 1997 | EP |
1 056 884 | Dec 2001 | EP |
1056884 | Dec 2001 | EP |
1 132 470 | Sep 2005 | EP |
1132470 | Sep 2005 | EP |
2332516 | Jun 1999 | GB |
4262799 | Sep 1992 | JP |
4304900 | Oct 1992 | JP |
5130869 | May 1993 | JP |
5146299 | Jun 1993 | JP |
2005304396 | Nov 2005 | JP |
WO 9416106 | Jul 1984 | WO |
WO 9416108 | Jul 1984 | WO |
WO 8909824 | Oct 1989 | WO |
WO 9011372 | Oct 1990 | WO |
WO 9106643 | May 1991 | WO |
WO 9108307 | Jun 1991 | WO |
WO 9116446 | Oct 1991 | WO |
WO 9201813 | Feb 1992 | WO |
WO 9424312 | Oct 1994 | WO |
WO 9503430 | Feb 1995 | WO |
WO 9503432 | Feb 1995 | WO |
WO 9525180 | Sep 1995 | WO |
WO 9522623 | Nov 1995 | WO |
WO 9535390 | Dec 1995 | WO |
WO 9600795 | Jan 1996 | WO |
WO 9614406 | May 1996 | WO |
WO 9633207 | Oct 1996 | WO |
WO 9802449 | Jan 1997 | WO |
WO 9707235 | Feb 1997 | WO |
WO 9814610 | Apr 1997 | WO |
WO 9717076 | May 1997 | WO |
WO 9717471 | May 1997 | WO |
WO 9719193 | May 1997 | WO |
WO 9720948 | Jun 1997 | WO |
WO 9742346 | Nov 1997 | WO |
WO 9804746 | Feb 1998 | WO |
WO 9816248 | Apr 1998 | WO |
WO 9839485 | Sep 1998 | WO |
WO 9918241 | Apr 1999 | WO |
WO 9931276 | Jun 1999 | WO |
WO 9954452 | Oct 1999 | WO |
WO 0004193 | Jan 2000 | WO |
WO 0015779 | Mar 2000 | WO |
WO 0015849 | Mar 2000 | WO |
WO 0036141 | Jun 2000 | WO |
WO 0070095 | Nov 2000 | WO |
WO 0071562 | Nov 2000 | WO |
WO 0120039 | Mar 2001 | WO |
WO 0127326 | Apr 2001 | WO |
WO 0138580 | May 2001 | WO |
WO 0140516 | Jun 2001 | WO |
WO 0161037 | Aug 2001 | WO |
WO 0164952 | Sep 2001 | WO |
WO 0177390 | Oct 2001 | WO |
WO 0179420 | Oct 2001 | WO |
WO 0188190 | Nov 2001 | WO |
WO 0197616 | Dec 2001 | WO |
WO 0200934 | Jan 2002 | WO |
WO 0202792 | Jan 2002 | WO |
WO 02053780 | Jul 2002 | WO |
WO 02077256 | Oct 2002 | WO |
WO 02103058 | Dec 2002 | WO |
WO 03008538 | Jan 2003 | WO |
WO 03033724 | Apr 2003 | WO |
WO 03066908 | Aug 2003 | WO |
WO 03072809 | Sep 2003 | WO |
WO 2004009814 | Jan 2004 | WO |
WO 2004058987 | Jul 2004 | WO |
WO 2004061119 | Jul 2004 | WO |
Number | Date | Country | |
---|---|---|---|
20100015602 A1 | Jan 2010 | US |